Temozolomide in children with progressive low-grade glioma

We conducted a phase II study to assess the efficacy of oral temozolomide (TMZ) in children with progressive low-grade glioma. Thirty eligible patients were enrolled on this study. Median age at enrollment was 10 years (range, 4–18 years). Eligible patients received TMZ (200 mg/m(2) per day) by mout...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gururangan, Sridharan, Fisher, Michael J., Allen, Jeffrey C., Herndon, James E., Quinn, Jennifer A., Reardon, David A., Vredenburgh, James J., Desjardins, Annick, Phillips, Peter C., Watral, Melody A., Krauser, Jeanne M., Friedman, Allan H., Friedman, Henry S.
Formato: Artigo
Idioma:Inglês
Publicado em: Duke University Press 2007
Assuntos:
Special Focus: Pediatric Neuro-Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1871667/
https://ncbi.nlm.nih.gov/pubmed/17347491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/15228517-2006-030
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados